Home > Insights > boult.bites Biotech – Winter 2014
13 February, 2014

The end of 2013 saw a flurry of activity in the SPC world as the CJEU handed down its judgements in cases C-484/12 (Georgetown University v Octrooicentrum Nederland), C-443/12(Actavis Group v Sanofi) and C-493/12 (Eli Lilly v HGS). These decisions have been eagerly awaited, because the referrals to the court addressed two key issues: (I) can a Patentee obtain more than one SPC per patent and (II) what is a “product protected by a basic patent in force” under Article 3(a) of Regulation No. 469/2009 (the SPC Regulation).

 

PDF icon Download the PDF

 

Authors

Joanna Peak Partner Biotechnology Patents Firm

Joanna Peak
Partner

Phone this number +44 (0)20 7430 7500

Email this address jpeak@boult.com

Salisbury Square House
8 Salisbury Square
London
EC4Y 8AP

Jennifer O'Farrell Partner Biotechnology Patent Firm

Jennifer O’Farrell
Partner

Phone this number +44 (0)20 7430 7500

Email this address jo'farrell@boult.com

Salisbury Square House
8 Salisbury Square
London
EC4Y 8AP

Edward Ronan Patent Attorney

Edward Ronan
Patent Attorney

Phone this number +44 (0)20 7430 7500

Email this address eronan@boult.com

Salisbury Square House
8 Salisbury Square
London
EC4Y 8AP